title: Ocular neuromyotonia.
abstract: OBJECTIVE
  Ocular neuromyotonia is characterised by spontaneous spasm of extraocular muscles and has been described in only 14 patients. Three further cases, two with unique features, are described, and the underlying mechanism reviewed in the light of recent experimental evidence implicating extracellular potassium concentration in causing spontaneous firing in normal and demyelinated axons.
  
  
  METHODS
  Two patients had third nerve neuromyotonia, one due to compression by an internal carotid artery aneurysm, which has not been reported previously, while the other followed irradiation of a pituitary tumour, a common association in the published reports. Selective activation occurred in both, where neuromyotonic activity was triggered by prolonged voluntary activation of specific extraocular muscles with or without spread of activity to other third nerve muscles. The other patient had fourth nerve involvement, where spasms of the superior oblique muscle were induced only by alcohol, a phenomenon which has not been described.
  
  
  RESULTS
  The two patients with third nerve involvement responded to carbamazepine and in one, an improvement in a chronic partial third nerve paresis occurred. The other has not required treatment and remains asymptomatic by refraining from alcohol.
  
  
  CONCLUSIONS
  A careful examination, including the effects of prolonged voluntary muscle action is required to initiate episodes and to demonstrate selective activation. Imaging is mandatory to exclude compressive intracranial lesions, particularly where there is no history of pituitary fossa irradiation. A trial of anticonvulsants should be considered in all patients. Extracellular potassium may play a role in spontaneous firing and ephatic transmission in ocular neuromyotonia.
authors.affiliation: Medical Eye Unit, St Thomas's Hospital, London.
authors.forename: E
authors.initials: E
authors.lastname: Ezra
authors.forename: D
authors.initials: D
authors.lastname: Spalton
authors.forename: M D
authors.initials: MD
authors.lastname: Sanders
authors.forename: E M
authors.initials: EM
authors.lastname: Graham
authors.forename: G T
authors.initials: GT
authors.lastname: Plant
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use; D002340:Carotid Artery Diseases / Q000150:complications / Q000473:pathology; D002343:Carotid Artery, Internal / Q000473:pathology; D000431:Ethanol / Q000009:adverse effects; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009222:Myotonia / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D009460:Neurologic Examination; D015835:Ocular Motility Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D009802:Oculomotor Nerve / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000150:complications; D013035:Spasm / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000431:Ethanol